Cargando…

Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial

BACKGROUND: To evaluate the additive effects of orthokeratology (OK) lenses and 0.01% atropine on slowing axial elongation in myopic children. METHODS: A prospective, randomized, double-blinded, placebo-controlled trial was conducted over a 12-month period. Sixty children aged 8 to 12 years with sph...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shiao, Du, Liping, Ji, Na, Li, Binbin, Pang, Xuena, li, Xiuhong, Ma, Nana, Huang, Congcong, Fu, Aicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665032/
https://www.ncbi.nlm.nih.gov/pubmed/36380280
http://dx.doi.org/10.1186/s12886-022-02635-0
_version_ 1784831208983625728
author Yu, Shiao
Du, Liping
Ji, Na
Li, Binbin
Pang, Xuena
li, Xiuhong
Ma, Nana
Huang, Congcong
Fu, Aicun
author_facet Yu, Shiao
Du, Liping
Ji, Na
Li, Binbin
Pang, Xuena
li, Xiuhong
Ma, Nana
Huang, Congcong
Fu, Aicun
author_sort Yu, Shiao
collection PubMed
description BACKGROUND: To evaluate the additive effects of orthokeratology (OK) lenses and 0.01% atropine on slowing axial elongation in myopic children. METHODS: A prospective, randomized, double-blinded, placebo-controlled trial was conducted over a 12-month period. Sixty children aged 8 to 12 years with spherical equivalent refraction from − 1.00 to -4.00 D who had been wearing OK lenses successfully for 2 months (as baseline) were randomly assigned in a 1:1 ratio to combination group (combination of OK lens and 0.01% atropine eye drops) and control group (combination of OK lens and placebo). The primary outcome was change in axial length, along with secondary outcomes including change in pupil diameter (PD) and accommodative amplitude (AMP) at 12 months (measured at 4-month intervals). RESULTS: After 12 months, the overall axial elongation was 0.10 ± 0.14 mm and 0.20 ± 0.15 mm (p = 0.01) in the combination and control groups, respectively. The change in axial length in the two groups showed significant differences only in the first four months (median [Q1, Q3] (95% CI), -0.01 mm [-0.07, 0.05] (-0.06, 0.04) vs. 0.04 mm [0.00, 0.10] (0.02, 0.09); p = 0.04), but no difference thereafter. Multivariate linear regression analysis showed that the axial elongation was significantly slower in the combination group than in the control group (standard β = -0.10, p = 0.02). PD significantly increased by 0.45 mm [0.20, 0.68] at the 4th month visit (p < 0.001) and then remained stable in the combination group. The PD in the control group and AMP in the two groups remained stable from baseline to 12 months (all p > 0.05). CONCLUSION: The combination therapy was more effective than the OK lens alone in slowing axial elongation after 12 months of treatment, and mainly in the first 4 months. TRIAL REGISTRATION: The First Affiliated Hospital of Zhengzhou University, ChiCTR2000033904. Registered 16/06/2020, http://www.chictr.org.cn/login.aspx?referurl=%2flistbycreater.aspx
format Online
Article
Text
id pubmed-9665032
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96650322022-11-16 Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial Yu, Shiao Du, Liping Ji, Na Li, Binbin Pang, Xuena li, Xiuhong Ma, Nana Huang, Congcong Fu, Aicun BMC Ophthalmol Research BACKGROUND: To evaluate the additive effects of orthokeratology (OK) lenses and 0.01% atropine on slowing axial elongation in myopic children. METHODS: A prospective, randomized, double-blinded, placebo-controlled trial was conducted over a 12-month period. Sixty children aged 8 to 12 years with spherical equivalent refraction from − 1.00 to -4.00 D who had been wearing OK lenses successfully for 2 months (as baseline) were randomly assigned in a 1:1 ratio to combination group (combination of OK lens and 0.01% atropine eye drops) and control group (combination of OK lens and placebo). The primary outcome was change in axial length, along with secondary outcomes including change in pupil diameter (PD) and accommodative amplitude (AMP) at 12 months (measured at 4-month intervals). RESULTS: After 12 months, the overall axial elongation was 0.10 ± 0.14 mm and 0.20 ± 0.15 mm (p = 0.01) in the combination and control groups, respectively. The change in axial length in the two groups showed significant differences only in the first four months (median [Q1, Q3] (95% CI), -0.01 mm [-0.07, 0.05] (-0.06, 0.04) vs. 0.04 mm [0.00, 0.10] (0.02, 0.09); p = 0.04), but no difference thereafter. Multivariate linear regression analysis showed that the axial elongation was significantly slower in the combination group than in the control group (standard β = -0.10, p = 0.02). PD significantly increased by 0.45 mm [0.20, 0.68] at the 4th month visit (p < 0.001) and then remained stable in the combination group. The PD in the control group and AMP in the two groups remained stable from baseline to 12 months (all p > 0.05). CONCLUSION: The combination therapy was more effective than the OK lens alone in slowing axial elongation after 12 months of treatment, and mainly in the first 4 months. TRIAL REGISTRATION: The First Affiliated Hospital of Zhengzhou University, ChiCTR2000033904. Registered 16/06/2020, http://www.chictr.org.cn/login.aspx?referurl=%2flistbycreater.aspx BioMed Central 2022-11-15 /pmc/articles/PMC9665032/ /pubmed/36380280 http://dx.doi.org/10.1186/s12886-022-02635-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yu, Shiao
Du, Liping
Ji, Na
Li, Binbin
Pang, Xuena
li, Xiuhong
Ma, Nana
Huang, Congcong
Fu, Aicun
Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
title Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
title_full Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
title_fullStr Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
title_full_unstemmed Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
title_short Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
title_sort combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665032/
https://www.ncbi.nlm.nih.gov/pubmed/36380280
http://dx.doi.org/10.1186/s12886-022-02635-0
work_keys_str_mv AT yushiao combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT duliping combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT jina combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT libinbin combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT pangxuena combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT lixiuhong combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT manana combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT huangcongcong combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial
AT fuaicun combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial